Lisata Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Lisata Therapeutics (LSTA).

Price Target Range — 4 Quarters

Analyst Consensus — 2 Analysts

2Hold

# Analysts2

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 15, 2026	HC Wainwright & Co.	Joseph Pantginis	Downgrade	Buy→Neutral	—
Jan 21, 2026	Brookline Capital	Kemp Dolliver	Downgrade	Buy→Hold	—
Aug 21, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Jul 15, 2025	Brookline Capital	Kemp Dolliver	PT Raise	Buy	$20→$32
Dec 11, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Nov 21, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Sep 18, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Aug 13, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Jul 19, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Jul 10, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Jun 14, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
May 21, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Apr 26, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Apr 25, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Mar 1, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15
Jan 4, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$15

Analyst Ratings News

PRO
HC Wainwright & Co. Downgrades Lisata Therapeutics to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades Lisata Therapeutics (NASDAQ:LSTA) from Buy to Neutral.

Benzinga Newsdesk

PRO
Brookline Capital Downgrades Lisata Therapeutics to Hold

Brookline Capital analyst Kemp Dolliver downgrades Lisata Therapeutics (NASDAQ:LSTA) from Buy to Hold.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
Brookline Capital Maintains Buy on Lisata Therapeutics, Raises Price Target to $32

Brookline Capital maintains Lisata Therapeutics (NASDAQ:LSTA) with a Buy and raises the price target from $20 to $32.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:LSTA) with a Buy and maintains $15 price target.

Benzinga Newsdesk

Lisata Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Lisata Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Downgrades Lisata Therapeutics to Neutral

PRO
Brookline Capital Downgrades Lisata Therapeutics to Hold

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PRO
Brookline Capital Maintains Buy on Lisata Therapeutics, Raises Price Target to $32

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

People Also Watch

People Also Watch

Lisata Therapeutics Inc

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

Lisata Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Downgrades Lisata Therapeutics to Neutral

PROBrookline Capital Downgrades Lisata Therapeutics to Hold

PROHC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PROBrookline Capital Maintains Buy on Lisata Therapeutics, Raises Price Target to $32

PROHC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PROHC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Downgrades Lisata Therapeutics to Neutral

PRO
Brookline Capital Downgrades Lisata Therapeutics to Hold

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PRO
Brookline Capital Maintains Buy on Lisata Therapeutics, Raises Price Target to $32

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target